Clinical Trial Update: Tofacitinib for Immune Skin Conditions in Down Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tofacitinib for immune-mediated skin conditions in individuals with Down syndrome has completed, with results posted. The study exami…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata
• Atopic Dermatitis
• Down Syndrome
• Hidradenitis Suppurativa
• Psoriasis
• Vitiligo

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Down Syndrome, Alopecia Areata | Phase 2 | Status: COMPLETED | Results posted: 2025-12-11